Skip to main content

Be confident that your patient care is up to date

Register now and start receiving our tailored medical education content from April. You can also secure your place for the first live webinar.

Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video

IN FOCUS | GLP-1 receptor agonists

Syringe and pills

11-01-2022 | SGLT2 inhibitors | News

Real-world adjunctive medication outcomes in type 1 diabetes revealed

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

IN FOCUS | Hypoglycemia

Data for health analytics concept

03-03-2023 | Healthcare systems | News

Health informatics system aids timely, equitable diabetes care

A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers.

IN FOCUS | Cardiovascular disorders

Human heart with ecg graph. 3d illustration

11-18-2022 | Dapagliflozin | News

Dapagliflozin HFpEF benefits independent of glucose levels

People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.

IN FOCUS | Kidney disease

Close up of urinalysis with reagent strips

11-10-2022 | Nephropathy | News

‘Strong justification’ for individualized albuminuria screening in type 1 diabetes

Screening people with type 1 diabetes for albuminuria at intervals determined by their baseline albumin excretion rate and glycated hemoglobin level reduces the time spent with undetected kidney disease, show DCCT/EDIC data.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

IN FOCUS | Obesity & lifestyle interventions

Tape measure - overweight obesity concept

02-14-2023 | Obesity | News

Obesity as prevalent in type 1 diabetes as general US population

There is a “substantial” burden of overweight and obesity among people with type 1 diabetes, say US researchers who found rates to be in line with that of the general population.

IN FOCUS | SGLT2 inhibitors

Close up of mixed medications

12-09-2022 | Medications | News

TriMaster data support ‘try before you choose’ for type 2 diabetes medications

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

IN FOCUS | Hyperglycemia

X-ray of fractured forearm shaft of radius and ulnar bone on red mark

05-24-2022 | Bone health | News

Poor glycemic control, kidney disease linked to bone fragility in type 1 diabetes

Higher glycated hemoglobin and the presence of kidney disease are associated with lower bone mineral density in people with type 1 diabetes, study results show.

IN FOCUS | Pediatric type 2 diabetes

Weekly pill container

04-04-2022 | Dapagliflozin | News

Phase 3 trial supports dapagliflozin in young people with type 2 diabetes

The first phase 3 trial of an SGLT2 inhibitor in children and young people with type 2 diabetes shows that dapagliflozin significantly improves their glucose control – as long as they remember to take it.

IN FOCUS | Tirzepatide

Person standing on weigh scales with tape measure in foreground

06-04-2022 | ADA 2022 | Conference coverage | News

​​​​​​​SURMOUNT-1 places tirzepatide weight loss efficacy within surgical range

A weekly injection of tirzepatide results in a substantial bodyweight reduction over and above that achieved with lifestyle intervention in people with obesity, show the SURMOUNT-1 findings.

IN FOCUS | Mental health & psychosocial care

Lori Berard

04-14-2022 | Hyperglycemia | View from the clinic | Article

Managing hyperglycemia related to stress

Lori Berard highlights the contribution of stress to poor glycemic control and considers how healthcare providers can account for this in their practice.